Baidu
map

Hypertension:研究发现内源性多肽对高血压疗效显著

2013-12-17 张雯雯 中国科学报

记者近日从中科院昆明动物所获悉,该所赖仞课题组和华中科技大学教授丁久平合作发现,人体内一种内源性多肽对高血压有很好的治疗作用。相关成果发表于美国心脏协会《高血压》杂志。 高血压是最常见的慢性病,也是心脑血管病最主要的危险因素。其主要并发症有:脑卒中、心肌梗死、心力衰竭和慢性肾脏病。随着生活水平的提高,高血压患者的人数逐年增加,因此治疗高血压的药物一直是药物研发的热点。 此次研究人员发现,人体内

记者近日从中科院昆明动物所获悉,该所赖仞课题组和华中科技大学教授丁久平合作发现,人体内一种内源性多肽对高血压有很好的治疗作用。相关成果发表于美国心脏协会《高血压》杂志。【原文下载

高血压是最常见的慢性病,也是心脑血管病最主要的危险因素。其主要并发症有:脑卒中、心肌梗死、心力衰竭和慢性肾脏病。随着生活水平的提高,高血压患者的人数逐年增加,因此治疗高血压的药物一直是药物研发的热点。

此次研究人员发现,人体内一种内源性多肽能选择性地作用于BK通道上的β亚基,对高血压有很好的治疗作用。他们进一步利用猴的高血压模型验证治疗效果,发现该多肽能显著降低血管的舒张压和收缩压,同时能明显降低血流速度。因此,该多肽有可能被开发成一种新型治疗高血压疾病的药物。

原文出处:

Liu R, Zhang Z, Liu H, Hou P, Lang J, Wang S, Yan H, Li P, Huang Z, Wu H, Rong M, Huang J, Wang H, Lv L, Qiu M, Ding J, Lai R.Human β-defensin 2 is a novel opener of Ca2+-activated potassium channels and induces vasodilation and hypotension in monkeys.Hypertension. 2013 Aug;62(2):415-25. doi: 10.1161/HYPERTENSIONAHA.111.01076. 【原文下载

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1725559, encodeId=f15c1e2555929, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Mar 14 03:41:00 CST 2014, time=2014-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038479, encodeId=eb5320384e9b1, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Thu May 01 02:41:00 CST 2014, time=2014-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1753044, encodeId=68701e53044d9, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Sun Mar 23 22:41:00 CST 2014, time=2014-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682007, encodeId=7e71168200eec, content=<a href='/topic/show?id=15593040e9a' target=_blank style='color:#2F92EE;'>#内源性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30407, encryptionId=15593040e9a, topicName=内源性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b46b27929604, createdName=diushouji, createdTime=Fri Jun 13 12:41:00 CST 2014, time=2014-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501033, encodeId=fe4515010336a, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Thu Dec 19 04:41:00 CST 2013, time=2013-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530025, encodeId=329d1530025b7, content=<a href='/topic/show?id=fd6f4340017' target=_blank style='color:#2F92EE;'>#多肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43400, encryptionId=fd6f4340017, topicName=多肽)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cdb812012363, createdName=fusion, createdTime=Thu Dec 19 04:41:00 CST 2013, time=2013-12-19, status=1, ipAttribution=)]
    2014-03-14 feather89
  2. [GetPortalCommentsPageByObjectIdResponse(id=1725559, encodeId=f15c1e2555929, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Mar 14 03:41:00 CST 2014, time=2014-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038479, encodeId=eb5320384e9b1, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Thu May 01 02:41:00 CST 2014, time=2014-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1753044, encodeId=68701e53044d9, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Sun Mar 23 22:41:00 CST 2014, time=2014-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682007, encodeId=7e71168200eec, content=<a href='/topic/show?id=15593040e9a' target=_blank style='color:#2F92EE;'>#内源性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30407, encryptionId=15593040e9a, topicName=内源性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b46b27929604, createdName=diushouji, createdTime=Fri Jun 13 12:41:00 CST 2014, time=2014-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501033, encodeId=fe4515010336a, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Thu Dec 19 04:41:00 CST 2013, time=2013-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530025, encodeId=329d1530025b7, content=<a href='/topic/show?id=fd6f4340017' target=_blank style='color:#2F92EE;'>#多肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43400, encryptionId=fd6f4340017, topicName=多肽)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cdb812012363, createdName=fusion, createdTime=Thu Dec 19 04:41:00 CST 2013, time=2013-12-19, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1725559, encodeId=f15c1e2555929, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Mar 14 03:41:00 CST 2014, time=2014-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038479, encodeId=eb5320384e9b1, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Thu May 01 02:41:00 CST 2014, time=2014-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1753044, encodeId=68701e53044d9, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Sun Mar 23 22:41:00 CST 2014, time=2014-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682007, encodeId=7e71168200eec, content=<a href='/topic/show?id=15593040e9a' target=_blank style='color:#2F92EE;'>#内源性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30407, encryptionId=15593040e9a, topicName=内源性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b46b27929604, createdName=diushouji, createdTime=Fri Jun 13 12:41:00 CST 2014, time=2014-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501033, encodeId=fe4515010336a, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Thu Dec 19 04:41:00 CST 2013, time=2013-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530025, encodeId=329d1530025b7, content=<a href='/topic/show?id=fd6f4340017' target=_blank style='color:#2F92EE;'>#多肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43400, encryptionId=fd6f4340017, topicName=多肽)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cdb812012363, createdName=fusion, createdTime=Thu Dec 19 04:41:00 CST 2013, time=2013-12-19, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1725559, encodeId=f15c1e2555929, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Mar 14 03:41:00 CST 2014, time=2014-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038479, encodeId=eb5320384e9b1, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Thu May 01 02:41:00 CST 2014, time=2014-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1753044, encodeId=68701e53044d9, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Sun Mar 23 22:41:00 CST 2014, time=2014-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682007, encodeId=7e71168200eec, content=<a href='/topic/show?id=15593040e9a' target=_blank style='color:#2F92EE;'>#内源性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30407, encryptionId=15593040e9a, topicName=内源性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b46b27929604, createdName=diushouji, createdTime=Fri Jun 13 12:41:00 CST 2014, time=2014-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501033, encodeId=fe4515010336a, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Thu Dec 19 04:41:00 CST 2013, time=2013-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530025, encodeId=329d1530025b7, content=<a href='/topic/show?id=fd6f4340017' target=_blank style='color:#2F92EE;'>#多肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43400, encryptionId=fd6f4340017, topicName=多肽)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cdb812012363, createdName=fusion, createdTime=Thu Dec 19 04:41:00 CST 2013, time=2013-12-19, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1725559, encodeId=f15c1e2555929, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Mar 14 03:41:00 CST 2014, time=2014-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038479, encodeId=eb5320384e9b1, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Thu May 01 02:41:00 CST 2014, time=2014-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1753044, encodeId=68701e53044d9, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Sun Mar 23 22:41:00 CST 2014, time=2014-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682007, encodeId=7e71168200eec, content=<a href='/topic/show?id=15593040e9a' target=_blank style='color:#2F92EE;'>#内源性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30407, encryptionId=15593040e9a, topicName=内源性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b46b27929604, createdName=diushouji, createdTime=Fri Jun 13 12:41:00 CST 2014, time=2014-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501033, encodeId=fe4515010336a, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Thu Dec 19 04:41:00 CST 2013, time=2013-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530025, encodeId=329d1530025b7, content=<a href='/topic/show?id=fd6f4340017' target=_blank style='color:#2F92EE;'>#多肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43400, encryptionId=fd6f4340017, topicName=多肽)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cdb812012363, createdName=fusion, createdTime=Thu Dec 19 04:41:00 CST 2013, time=2013-12-19, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1725559, encodeId=f15c1e2555929, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Mar 14 03:41:00 CST 2014, time=2014-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038479, encodeId=eb5320384e9b1, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Thu May 01 02:41:00 CST 2014, time=2014-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1753044, encodeId=68701e53044d9, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Sun Mar 23 22:41:00 CST 2014, time=2014-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682007, encodeId=7e71168200eec, content=<a href='/topic/show?id=15593040e9a' target=_blank style='color:#2F92EE;'>#内源性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30407, encryptionId=15593040e9a, topicName=内源性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b46b27929604, createdName=diushouji, createdTime=Fri Jun 13 12:41:00 CST 2014, time=2014-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501033, encodeId=fe4515010336a, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Thu Dec 19 04:41:00 CST 2013, time=2013-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530025, encodeId=329d1530025b7, content=<a href='/topic/show?id=fd6f4340017' target=_blank style='color:#2F92EE;'>#多肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43400, encryptionId=fd6f4340017, topicName=多肽)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cdb812012363, createdName=fusion, createdTime=Thu Dec 19 04:41:00 CST 2013, time=2013-12-19, status=1, ipAttribution=)]
    2013-12-19 fusion
Baidu
map
Baidu
map
Baidu
map